SequelSEC

Minerva Neurosciences, Inc. NERV

Pharmaceutical Preparations · CIK 0001598646 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$21.85M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Minerva Neurosciences, Inc. (NERV) reported revenue of $0 and net income of $1.44M for the fiscal year ended 2024-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Minerva Neurosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Minerva Neurosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$0$0$0$0$41.18M$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$21.85M-$23.12M-$25.23M-$45.37M$1.85M-$75.87M-$51.73M-$41.17M
Net income$1.44M-$30.01M-$32.11M-$49.91M$1.94M-$72.18M-$50.17M-$31.52M
Research & development$11.90M$12.71M$14.65M$32.04M$22.04M$58.12M$34.89M$30.26M
Weighted-average diluted sharesshares 7.57Mshares 6.51Mshares 5.34Mshares 5.34Mshares 40.92Mshares 39.01MUnavailableUnavailable
Pretax incomeUnavailableUnavailable-$32.11M-$51.71M$1.94M-$74.44M-$50.17M-$40.90M
Income tax expenseUnavailableUnavailableUnavailable-$1.80MUnavailable-$2.25M$0-$9.40M
Diluted EPS$0.19$-4.61$-6.01$-9.35$0.05$-1.85UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.95M$10.41M$10.58M$13.33M$17.29M$17.74M$16.84M$10.91M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Minerva Neurosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$21.36M$40.91M$36.09M$60.76M$25.36M$21.41M$50.23M$26.05M
Total assets$37.14M$56.90M$55.09M$77.12M$57.63M$77.50M$139.14M$183.70M
Current assets$22.27M$42.00M$40.16M$62.20M$27.44M$47.14M$90.02M$129.54M
Total liabilities$62.84M$85.36M$75.11M$69.15M$4.96M$49.72M$48.87M$52.10M
Current liabilities$2.84M$3.34M$1.38M$2.82M$3.16M$6.63M$3.61M$6.84M
Total equity incl. NCI-$25.69M-$28.46M-$20.02M$7.98M$52.66M$27.78M$90.26M$131.60M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.61M$1.81M$969.67K$1.85M$995.61K$2.32M$1.80M$1.44M

Cash flow

Minerva Neurosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$19.55M-$14.78M-$24.65M-$24.60M-$33.82M-$43.43M-$41.94M$3.09M
Capital expendituresUnavailableUnavailable$16.33KUnavailableUnavailableUnavailableUnavailable$52.40K
Investing cash flow$0$0-$16.33KUnavailable$24.53M$14.08M$69.49M-$107.19M
Financing cash flowUnavailable$19.60M-$5$60.00M$13.24M$525.00K-$3.34M$47.17M
Net change in cash-$19.55M$4.82M-$24.66M$35.40M$3.94M-$28.82M$24.20M-$56.93M
Stock-based compensation$1.33M$1.97M$4.11M$5.22M$9.70M$9.17M$8.18M$5.03M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$389
Depreciation & amortization$5.44K$5.44KUnavailableUnavailable$16.01K$17.47K$17.47K$11.09K

Derived

Minerva Neurosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flowUnavailableUnavailable-$24.66MUnavailableUnavailableUnavailableUnavailable$3.04M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable4.5%UnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable23.6%UnavailableUnavailableUnavailable
Current ratio7.85x12.57x29.15x22.07x8.68x7.11x24.94x18.94x
Revenue YoY growthUnavailableUnavailableUnavailable-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable4.7%UnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable53.5%UnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NERV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.